_pptx-Photoroom.png)
About Us
Senticell is a pioneering biotechnology company driven by a bold, transformative idea: red blood cells (RBCs) are not just oxygen carriers-they are dynamic immune sensors. Our cutting-edge research has revealed that RBCs transport molecular signals from across the body, offering a powerful and previously untapped gateway for diagnostics and therapeutic intervention. By harnessing this cellular intelligence, we aim to detect diseases earlier, treat them more precisely, and monitor them with unmatched accuracy.
Founded on groundbreaking research at the University of Pennsylvania, Senticell is led by Dr. Nilam Mangalmurti, a distinguished physician-scientist, alongside a diverse team of immunologists, cell biologists, and engineers. Our proprietary platforms enable the detection of disease-specific RNA and protein signatures using a simple blood sample-enabling rapid, low-cost, and highly scalable diagnostics.
Beyond diagnostics, our revolutionary RBC-based therapeutic platform offers precise immune modulation and targeted delivery of RNA and small-molecule drugs. Uniquely, this approach avoids triggering immune rejection-making it ideal for treating complex conditions such as cancer, sepsis, autoimmune disorders, and neurodegenerative diseases.
From academic discovery to real-world clinical application, Senticell is redefining the boundaries of cell-based medicine. By transforming the most abundant human cell into a vehicle for powerful diagnostic and therapeutic tools, we are shaping a new era of personalized, precision healthcare.
